Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Tack, Jan; Stanghellini, Vincenzo; Mearin, Fermin; Yiannakou, Yan; Layer, Peter; Coffin, Benoit; Simren, Magnus; Mackinnon, Jonathan; Wiseman, Gwen; Marciniak, Anne; Bouchoucha,; Ducrotte,; Macaigne,; Mion,; Schneider,; Le, Sidanier; Tardy,; Zerbib,; Andresen,; Bischoff,; Jander,; Jung,; Krammer,; Langhorst,; Omankowsky,; Schiefke,; Steuer,; Van, der Voort; Von, Arnim; Annese,; Cuomo,; De, Angelis; Di, Mario; Di, Stefano; Ferrini,; Gasbarrini,; Giaccobe,; Marchi,; Marzio,; Repici,; Savarino,; Angos,; Berdier,; Brotons,; Caballero-Plasencia,; Clave,; Fort,; Garcia,; Gomez,; Martinez,; Perello,; Rey,; Sanchez-Antolin,; Serra,; Tantina,; Toran,; Ekesbo,; Hellstrom,; Kjellstrom,; Lindberg,; Walter,; Arebi,; Bridger,; Butt,; Emmanuel,; Eugenicos,; Kaushik,; Millar,; Sanders,; Whorwell,

doi:10.1186/s12876-019-0985-1

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Author:

Tack, Jan

Stanghellini, Vincenzo ; Mearin, Fermin ; Yiannakou, Yan ; Layer, Peter ; Coffin, Benoit ; Simren, Magnus ; Mackinnon, Jonathan ; Wiseman, Gwen ; Marciniak, Anne ; Bouchoucha, ; Ducrotte, ; Macaigne, ; Mion, ; Schneider, ; Le, Sidanier ; Tardy, ; Zerbib, ; Andresen, ; Bischoff, ; Jander, ; Jung, ; Krammer, ; Langhorst, ; Omankowsky, ; Schiefke, ; Steuer, ; Van, der Voort ; Von, Arnim ; Annese, ; Cuomo, ; De, Angelis ; Di, Mario ; Di, Stefano ; Ferrini, ; Gasbarrini, ; Giaccobe, ; Marchi, ; Marzio, ; Repici, ; Savarino, ; Angos, ; Berdier, ; Brotons, ; Caballero-Plasencia, ; Clave, ; Fort, ; Garcia, ; Gomez, ; Martinez, ; Perello, ; Rey, ; Sanchez-Antolin, ; Serra, ; Tantina, ; Toran, ; Ekesbo, ; Hellstrom, ; Kjellstrom, ; Lindberg, ; Walter, ; Arebi, ; Bridger, ; Butt, ; Emmanuel, ; Eugenicos, ; Kaushik, ; Millar, ; Sanders, ; Whorwell,

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, IBS, IBS-C, Economic analysis, Healthcare resource utilisation, Europe, QUALITY-OF-LIFE, HEALTH-CARE COSTS, WORK PRODUCTIVITY, RETROSPECTIVE ANALYSIS, ACTIVITY IMPAIRMENT, UNITED-STATES, SYNDROME IBS, IMPACT, LINACLOTIDE, PREVALENCE, Adult, Aged, Constipation, Cost of Illness, Drug Costs, Facilities and Services Utilization, Female, Health Care Costs, Hospitalization, Humans, Irritable Bowel Syndrome, Male, Middle Aged, Office Visits, Prospective Studies, Retrospective Studies, Severity of Illness Index, Sick Leave, IBIS-C Study group, 1103 Clinical Sciences, 1117 Public Health and Health Services, 3202 Clinical sciences

Abstract:

BACKGROUND: Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). METHODS: An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. RESULTS: Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1. CONCLUSIONS: IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.